Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment

References

• Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124(1–2):95–107.
   PubMed Web of Science ®Google Scholar
• Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health. 2011;20(7):991–1006.
   PubMed Web of Science ®Google Scholar
• Greenfield SF, Brooks AJ, Gordon SM, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1–21.
   PubMed Web of Science ®Google Scholar
• McHugh RK, Devito EE, Dodd D, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013;45(1):38–43.
   PubMed Web of Science ®Google Scholar
• McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12–23.
   PubMed Web of Science ®Google Scholar
• Back SE, Payne RL, Wahlquist AH, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011;37(5):313–323.
   PubMed Web of Science ®Google Scholar
• Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–272.
   PubMed Web of Science ®Google Scholar
• Campbell ANC, Barbosa-Leiker C, Hatch-Maillette M, et al. Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict. 2018;27(6):465–470.
   PubMed Web of Science ®Google Scholar
• Leone B, Di Nicola M, Moccia L, et al. Gender-related psychopathology in opioid use disorder: results from a representative sample of Italian addiction services. Addict Behav. 2017;71:107–110.
   PubMed Web of Science ®Google Scholar
• Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.
   PubMed Web of Science ®Google Scholar
• Aljassem K, Raboud JM, Hart TA, et al. Gender Differences in severity and correlates of depression symptoms in people living with HIV in Ontario, Canada. J Int Assoc Provid AIDS Care. 2016;15(1):23–35.
   PubMedGoogle Scholar
• Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463–468.
   PubMed Web of Science ®Google Scholar
• Today’s Heroin Epidemic Infographics. https://www.cdc.gov/vitalsigns/heroin/infographic.html. Published 2015. Accessed May 29, 2019
   Google Scholar
• Mazure CM, Fiellin DA. Women and opioids: something different is happening here. The Lancet. 2018;392(10141):9–11.
   PubMed Web of Science ®Google Scholar
• Meyer JP, Isaacs K, El-Shahawy O, Burlew AK, Wechsberg W. Research on women with substance use disorders: reviewing progress and developing a research and implementation roadmap. Drug Alcohol Depend. 2019;197:158–163.
   PubMed Web of Science ®Google Scholar
• The National Center on Addiction and Substance Abuse at Columbia University. Behind bars II: substance abuse and America’s prison population. https://www.ojp.gov/ncjrs/virtual-library/abstracts/behind-bars-ii-substance-abuse-and-americas-prison-population. Published 2010.
   Google Scholar
• Springer SA, Di Paola A, Azar MM, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr. 2018;78(1):43–53.
   PubMed Web of Science ®Google Scholar
• Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256–268.
   PubMed Web of Science ®Google Scholar
• Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37(2):209–218.
   PubMed Web of Science ®Google Scholar
• Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158–170.
   PubMed Web of Science ®Google Scholar
• Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2018;79(1):92–100.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 (Suppl 20):22–33. quiz 4–57.
   PubMed Web of Science ®Google Scholar
• Wang J, Kelly BC, Booth BM, Falck RS, Leukefeld C, Carlson RG. Examining factorial structure and measurement invariance of the Brief Symptom Inventory (BSI)-18 among drug users. Addict Behav. 2010;35(1):23–29.
   PubMed Web of Science ®Google Scholar
• Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
   PubMed Web of Science ®Google Scholar
• Delate T, Coons SJ. The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. Clin Ther. 2000;22(9):1112–1120.
   PubMed Web of Science ®Google Scholar
• Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–714.
   PubMed Web of Science ®Google Scholar
• Saunders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88(6):791–804.
   PubMed Web of Science ®Google Scholar
• Verhoeven KJF, Simonsen KL, McIntyre LM. Implementing false discovery rate control: increasing your power. Oikos. 2005;108(3):643–647.
   Web of Science ®Google Scholar
• Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158–165.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients' reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356–361.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Moore BA, O'Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict. 2010;19(1):53–58.
   PubMed Web of Science ®Google Scholar
• Lesko CR, Keil AP, Fojo AT, Chander G, Lau B, Moore RD. Recent substance use and probability of unsuppressed HIV viral load among persons on antiretroviral therapy in continuity care. Am J Epidemiol. 2019;188(10):1830–1837.
   PubMed Web of Science ®Google Scholar
• Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105(7):e5–e16.
   PubMed Web of Science ®Google Scholar
• Chitsaz E, Meyer JP, Krishnan A, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013;17(Suppl 2):S118–S27.
   PubMedGoogle Scholar
• Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004;94(7):1147–1151.
   PubMed Web of Science ®Google Scholar
• Lichtenstein B. Domestic violence in barriers to health care for HIV-positive women. AIDS Patient Care Stds. 2006;20(2):122–132.
   PubMed Web of Science ®Google Scholar
• Flower SM. Employment and Female Offenders: An Update of the Empirical Research. Washington, DC: U.S. Department of Justice, National Institute of Corrections; 2010.
   Google Scholar
• Rabkin JG, Johnson J, Lin SH, et al. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS. 1997;11(4):507–515.
   PubMed Web of Science ®Google Scholar
• Bengtson AM, Pence BW, Crane HM, et al. Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PloS One . 2016;11(8):e0160738.
   PubMed Web of Science ®Google Scholar
• Mbaba M, Brown SE, Wooditch A, et al. Prevalence, diagnosis, and treatment rates of mood disorders among opioid users under criminal justice supervision. Subst Use Misuse. 2018;53(9):1519–1528.
   PubMed Web of Science ®Google Scholar
• Di Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health Justice. 2014;2(1):11.
   Google Scholar
• Berenz EC, Roberson-Nay R, Latendresse SJ, et al. Posttraumatic stress disorder and alcohol dependence: epidemiology and order of onset. Psychol Trauma. 2017;9(4):485–492.
   PubMed Web of Science ®Google Scholar
• Machtinger EL, Wilson TC, Haberer JE, Weiss DS. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–2100.
   PubMed Web of Science ®Google Scholar
• Dansky BS, Saladin ME, Brady KT, Kilpatrick DG, Resnick HS. Prevalence of victimization and posttraumatic stress disorder among women with substance use disorders: comparison of telephone and in-person assessment samples. Int J Addict. 1995;30(9):1079–1099.
   PubMed Web of Science ®Google Scholar
• Barry DT, Pilver C, Potenza MN, Desai RA. Prevalence and psychiatric correlates of pain interference among men and women in the general population. J Psychiatr Res. 2012;46(1):118–127.
   PubMed Web of Science ®Google Scholar
• Risser J, Cates A, Rehman H, Risser W. Gender differences in social support and depression among injection drug users in Houston, Texas. Am J Drug Alcohol Abuse. 2010;36(1):18–24.
   PubMed Web of Science ®Google Scholar